How Is the Increasing Complexity of Modalities Reshaping CDMO Differentiation and Specialization Strategies?
BioDuro’s Chief Scientific Officer, Subas Sakya, recently contributed to a Pharma’s Almanac industry roundtable exploring how the growing complexity of therapeutic modalities is changing the way CDMOs differentiate their capabilities and expertise.
In his contribution, Subas discusses why advanced modalities require purpose-built capabilities and specialized scientific expertise and why meaningful differentiation comes from combining that specialization with integrated support across discovery and development.
BioDuro’s Perspective
Different modalities bring fundamentally different challenges, and there is no universal solution. Each requires its own specialized infrastructure, distinct scientific expertise, and a tailored development philosophy. A containment suite engineered for HPAPIs looks nothing like a peptide synthesis platform, and neither resembles the conjugation chemistry and heterogeneity analytics demanded by ADCs. Trying to serve these modalities without purpose-built capabilities is a disservice to sponsors and their programs.
At BioDuro, we’ve made deliberate investments in the areas where complexity is highest and the margin for error must be lowest. Across HPAPIs, ADCs, and peptides, we’ve built integrated capabilities spanning chemistry, biology and drug metabolism and pharmacokinetics (DMPK), streamlining drug discovery while keeping the science connected, the data coherent, and critical insights intact rather than lost in handoffs. As we continue expanding our chemistry, manufacturing, and controls (CMC) capabilities, we remain committed to helping innovators advance with confidence from discovery to development and beyond.
That end-to-end integration across genuinely specialized platforms is where we believe meaningful CDMO differentiation lies, not in claiming to do everything but in doing the hardest things exceptionally well.
Subas Sakya’s perspective was originally published as part of the Pharma’s Almanac industry roundtable, “How Is the Increasing Complexity of Modalities Reshaping CDMO Differentiation and Specialization Strategies?”
